Display options
Cite
Poulton AS, Hibbert EJ, Champion BL, et al. Stimulants for the Control of Hedonic Appetite. Front Pharmacol. 2016;7:105doi: 10.3389/fphar.2016.00105.
Poulton, A. S., Hibbert, E. J., Champion, B. L., & Nanan, R. K. (2016). Stimulants for the Control of Hedonic Appetite. Frontiers in pharmacology, 7105. https://doi.org/10.3389/fphar.2016.00105
Poulton, Alison S, et al. "Stimulants for the Control of Hedonic Appetite." Frontiers in pharmacology vol. 7 (2016): 105. doi: https://doi.org/10.3389/fphar.2016.00105
Poulton AS, Hibbert EJ, Champion BL, Nanan RK. Stimulants for the Control of Hedonic Appetite. Front Pharmacol. 2016 Apr 25;7:105. doi: 10.3389/fphar.2016.00105. eCollection 2016. PMID: 27199749; PMCID: PMC4843092.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Apr 25;7:105. doi: 10.3389/fphar.2016.00105. eCollection 2016.

Stimulants for the Control of Hedonic Appetite.

Frontiers in pharmacology

Alison S Poulton, Emily J Hibbert, Bernard L Champion, Ralph K H Nanan

Affiliations

  1. Sydney Medical School Nepean, The University of Sydney Penrith, NSW, Australia.
  2. Charles Perkins Centre Nepean, The University of Sydney Penrith, NSW, Australia.

PMID: 27199749 PMCID: PMC4843092 DOI: 10.3389/fphar.2016.00105

Abstract

The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behavior. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognized to be effective for treating obesity. However, stimulants can be abused for their euphoric effect. They induce euphoria via the same neural pathway that underlies their therapeutic effect in obesity. For this reason they have generally not been endorsed for use in obesity. Among the stimulants, only phentermine (either alone or in combination with topiramate) and bupropion (which has stimulant-like properties and is used in combination with naltrexone), are approved by the United States Food and Drug Administration (FDA) for obesity, although dexamphetamine and methylpenidate are approved and widely used for treating attention deficit hyperactivity disorder (ADHD) in adults and children. Experience gained over many years in the treatment of ADHD demonstrates that with careful dose titration, stimulants can be used safely. In obesity, improvement in mood and executive functioning could assist with the lifestyle changes necessary for weight control, acting synergistically with appetite suppression. The obesity crisis has reached the stage that strong consideration should be given to adequate utilization of this effective and inexpensive class of drug.

Keywords: appetite suppressants; dexamphetamine; hedonic appetite; obesity; phentermine; reward deficiency

References

  1. Obesity (Silver Spring). 2015 Apr;23 Suppl 1:S4-7 - PubMed
  2. Curr Psychiatry Rep. 2014 Oct;16(10):489 - PubMed
  3. Obesity (Silver Spring). 2015 Apr;23 Suppl 1:S7-11 - PubMed
  4. Biol Psychiatry. 2005 Jun 1;57(11):1397-409 - PubMed
  5. Arch Gen Psychiatry. 1972 Feb;26(2):97-100 - PubMed
  6. JAMA. 2016 Jan 12;315(2):150-63 - PubMed
  7. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63 - PubMed
  8. Expert Opin Pharmacother. 2015 Jun;16(8):1263-74 - PubMed
  9. J Clin Psychiatry. 1996 Jul;57(7):308-9 - PubMed
  10. Australas Psychiatry. 2014 Apr;22(2):174-8 - PubMed
  11. Drug Alcohol Depend. 2013 Nov 1;133(1):283-6 - PubMed
  12. Physiol Behav. 2007 Aug 15;91(5):566-72 - PubMed
  13. J Clin Endocrinol Metab. 2009 Dec;94(12 ):4898-906 - PubMed
  14. J Clin Invest. 2007 Jan;117(1):13-23 - PubMed
  15. Lancet. 2001 Feb 3;357(9253):354-7 - PubMed
  16. Front Endocrinol (Lausanne). 2015 Feb 09;6:14 - PubMed
  17. Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3191-200 - PubMed
  18. CNS Spectr. 2015 Dec;20(6):546-56 - PubMed
  19. Arch Gen Psychiatry. 1999 Dec;56(12):1073-86 - PubMed
  20. Obes Surg. 2015 Sep;25(9):1741-9 - PubMed
  21. J Correct Health Care. 2013 Jul;19(3):211-7 - PubMed
  22. J Addict Med. 2009 Mar;3(1):8-18 - PubMed
  23. Arch Intern Med. 1996 Jun 24;156(12):1302-6 - PubMed
  24. Encephale. 2010 Dec;36(6):461-71 - PubMed
  25. Lancet. 2010 Aug 14;376(9740):517-23 - PubMed
  26. N Engl J Med. 2005 Nov 17;353(20):2121-34 - PubMed
  27. Am J Psychiatry. 2004 Jul;161(7):1173-80 - PubMed
  28. J Neurochem. 1997 May;68(5):2032-7 - PubMed
  29. Curr Psychiatry Rep. 2015 May;17(5):35 - PubMed
  30. Br Med J. 1962 Jul 7;2(5296):40-3 - PubMed
  31. Obes Res. 2003 Jun;11(6):722-33 - PubMed
  32. J Health Econ. 2012 Jul;31(4):630-43 - PubMed
  33. Cell. 2015 Mar 26;161(1):133-45 - PubMed
  34. Nat Neurosci. 2012 Oct;15(10):1330-5 - PubMed
  35. Int J Obes (Lond). 2010 May;34(5):919-35 - PubMed
  36. Appetite. 2010 Feb;54(1):208-13 - PubMed
  37. Subst Use Misuse. 2014 Mar;49(4):405-17 - PubMed
  38. Drug Saf. 2010 Oct 1;33(10):821-42 - PubMed
  39. Emotion. 2011 Aug;11(4):938-50 - PubMed
  40. J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1011-23 - PubMed
  41. Nat Rev Neurosci. 2012 Mar 14;13(4):279-86 - PubMed
  42. Lancet. 2008 Nov 29;372(9653):1906-13 - PubMed
  43. N Engl J Med. 2011 Oct 27;365(17):1597-604 - PubMed
  44. JAMA Psychiatry. 2015 Mar;72(3):235-46 - PubMed
  45. Int J Obes (Lond). 2007 Mar;31(3):440-8 - PubMed
  46. Obes Res. 2002 Jul;10(7):633-41 - PubMed
  47. Br Med J. 1968 Feb 10;1(5588):352-4 - PubMed
  48. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58 - PubMed
  49. Am J Psychiatry. 2003 Nov;160(11):1909-18 - PubMed
  50. J Genet Syndr Gene Ther. 2013 Jun 3;4(136):14318 - PubMed
  51. Neuroimage. 2008 Dec;43(4):756-63 - PubMed
  52. J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 - PubMed
  53. Expert Opin Drug Saf. 2004 Jan;3(1):1-8 - PubMed
  54. Eur Neuropsychopharmacol. 2014 Feb;24(2):251-61 - PubMed
  55. Med J Aust. 2014 Feb 3;200(2):70 - PubMed
  56. Subst Abuse Rehabil. 2014 May 26;5:37-52 - PubMed
  57. Expert Opin Drug Saf. 2010 Nov;9(6):917-35 - PubMed
  58. JAMA. 2008 Apr 2;299(13):1547-60 - PubMed
  59. N Engl J Med. 2016 Jan 28;374(4):363-71 - PubMed
  60. Biol Psychiatry. 1978 Apr;13(2):283-90 - PubMed
  61. Neuropsychopharmacology. 1996 Apr;14(4):233-41 - PubMed
  62. N Engl J Med. 2015 May 14;372(20):1877-9 - PubMed
  63. Eur J Pharmacol. 2013 Oct 15;718(1-3):370-5 - PubMed
  64. Synapse. 2000 Nov;38(2):167-76 - PubMed
  65. Curr Opin Neurobiol. 2013 Aug;23(4):535-8 - PubMed
  66. Neurosci Biobehav Rev. 2014 Nov;47:203-24 - PubMed
  67. Int J Obes (Lond). 2010 Aug;34(8):1243-54 - PubMed

Publication Types